Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...

Novo Nordisk AS (NVO) reports a strong 26% increase in sales and operating profit, with significant growth in obesity care ...

The Danish pharmaceutical company’s blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter ...

The settlement filed in Newark, N.J. federal court comes after similar settlements with Eli Lilly and Sanofi last year. It ...

Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo Nordisk A/S dominates in diabetes and weight-loss drugs, particularly with semaglutide, making it a strong buy. Record investments in 2024 to enhance supply chain and production capacity ...

Novo Nordisk reported turnover from obesity treatments soared by 57 per cent to 65.1 billion Danish kroner last year, largely ...

Novo’s record profit from obesity drugs has given the Foundation a war chest to fund its philanthropic grants, although ...